The data in this study demonstrate that the AGGF1 protein therapy, i.e., the intraperitoneal injection of the purified recombinant AGGF1 protein, successfully attenuates TAA by blocking arterial dilatation and remodeling in three different mouse models, including a TAC-induced TAA model, a genetic TAA model, and a pharmacological BAPN-induced TAA model (Figs. 3, 8–9 and Supplementary Figs. S9–14, S19–21). This evidence concerns the gene AGGF1 and persistent truncus arteriosus.